Is Sertraline Effective At Reducing The Symptoms Of Anxiety In Those Diagnosed With Generalized Anxiety Disorder (GAD)? by Kassis, Kristina N
Philadelphia College of Osteopathic Medicine 
DigitalCommons@PCOM 
PCOM Physician Assistant Studies Student 
Scholarship Student Dissertations, Theses and Papers 
2020 
Is Sertraline Effective At Reducing The Symptoms Of Anxiety In 
Those Diagnosed With Generalized Anxiety Disorder (GAD)? 
Kristina N. Kassis 
Philadelphia College of Osteopathic Medicine 
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Kassis, Kristina N., "Is Sertraline Effective At Reducing The Symptoms Of Anxiety In Those Diagnosed 
With Generalized Anxiety Disorder (GAD)?" (2020). PCOM Physician Assistant Studies Student 
Scholarship. 528. 
https://digitalcommons.pcom.edu/pa_systematic_reviews/528 
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student 
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM 
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For 









Is Sertraline Effective At Reducing The Symptoms Of Anxiety In 







Kristina N. Kassis, PA-S 
 A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For 
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
  
   
Department of Physician Assistant Studies 









OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
sertraline is effective at reducing the symptoms of anxiety in those diagnosed with generalized 
anxiety disorder (GAD).  
 
STUDY DESIGN:  This is a systematic review of three randomized control trials (RCTs) 
published between 2008 and 2015, all in the English language and published in peer-reviewed 
journals. 
 
DATA SOURCES: Three randomized control trials that study the effects of sertraline for 
reduction of anxiety symptoms in patients with GAD, obtained using PubMed, CINAHL Plus 
and Academic Search Premier. 
 
OUTCOMES MEASURED: The primary outcome measured in each study was patient-reported 
reduction in anxiety symptoms and improvement of quality of life.  These outcomes were 
measured using several scales, including the Hamilton Rating Scale for Anxiety, the Pediatric 
Anxiety Rating Scale, the Children’s Global Assessment Scale, The Clinical Global Impression-
Improvement Scale, and the Clinical Global Impressions Severity Scale.  
 
RESULTS: Cvjetkovic-Bosnjak et al. found sertraline to be equally effective as pregabalin for 







CONCLUSION: The results of this systematic review show that sertraline is effective in treating 
the symptoms of anxiety in patients with a diagnosis of generalized anxiety disorder. While the 
results from these studies were promising, additional research with larger, more diverse 
populations, standardized measurements of outcomes, increased time frame, and further 
examination of adverse drug reactions and cost-effectiveness are required to determine the true 
long-term benefit of sertraline as therapy for GAD. 
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 Generalized anxiety disorder (GAD) is a chronic mental illness with a prevalence of 5-
7% in the general population.1 While the exact etiology of this illness is unknown, it is likely 
multifactorial, and has been linked to disrupted functional connectivity of the amygdala and its 
processing of fear. In addition to constant worry, the physiological effects of anxiety may include 
headache, paresthesias, fasciculations, vertigo, syncope, abdominal pain, nausea, vomiting or 
diarrhea, indigestion, dry mouth, shortness of breath, tachycardia, chest pain, palpitations, 
frequent urination, perspiration or excessive fatigue.3 GAD leads to functional impairment and 
significantly reduced patient’s quality of life.1 
 The economic burden of anxiety on the healthcare system is tremendous and cannot be 
ignored. Though there is not an exact estimate within the past few years, between 2009 and 2011 
there were an estimated 1,247,000 ED visits for anxiety annually, representing 0.93% of all ED 
visits in the United States.4 Additionally, it is estimated that between 2009 and 2010, the annual 
overall direct medical costs associated with anxiety disorders in the US was $1657.52 per person, 
or $33.71 billion in total.5   
 Many different methods have been used to treat GAD. According to the guidelines of the 
World Federation of Societies of Biological Psychiatry, first-line treatments for GAD are 
selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake 
inhibitors (SNRIs), and pregabalin, an atypical anxiolytic.1 Long-acting benzodiazepines such as 
diazepam are also recommended for the treatment of anxiety.6 Psychotherapy like CBT is 
recommended mostly in combination with pharmacotherapy.1 Despite the many options already 
available, few patients with GAD receive adequate treatment. In fact, according to a 2009 




national representative survey of 3,032 respondents in the United States, guideline-concordant 
care was received by only 32.5% of people with GAD in the primary care sector.7 
 While the aforementioned methods of treatment have had efficacy in treating anxiety, 
they are not without drawbacks. For example, Gale and Millichamp found that various drug 
treatments, such as benzodiazepines, buspirone, hydroxyzine, antidepressants, 
and pregabalin may all reduce symptoms of anxiety in people with GAD, but they can have 
unpleasant adverse effects, and most trials have been short term.8 Additionally,  Gale and 
Millichamp found that benzodiazepines, while effective, increase the risk of dependence, 
sedation, and accidents, and can be harmful to neonates if used during pregnancy.8 Furthermore, 
buspirone may be less effective in patients who have recently taken benzodiazepines.8  
 Sertraline is an SSRI that is already commonly used to treat other anxiety disorders. For 
example, treatment of panic disorder with sertraline results in a decrease in the number of panic 
attacks and an improved quality of life.9 Additionally, sertraline is effective for the treatment of 
social phobia.10 Though sertraline is generally not a first-line drug for the treatment of GAD, it 
may have benefits for patients with this condition as well, given its already-proven efficacy with 
other anxiety disorders. In this systematic review, the effectiveness of sertraline at reducing 
symptoms of anxiety in those diagnosed with GAD will be evaluated through three randomized 
control trials.  
OBJECTIVE  
 The objective of this selective EBM review is to determine whether or not sertraline is 
effective at reducing symptoms of anxiety in those diagnosed with generalized anxiety disorder.  
 
 





 The population studied in this systematic review was obtained from three randomized 
control trials that included patients suffering from symptoms of anxiety with a clinical diagnosis 
of GAD. Oral sertraline was the intervention studied in comparison with other methods of 
treating anxiety including pharmacologic therapy with buspirone and pregabalin, CBT and 
combination therapy.  The key words employed in the author’s search for sources via PubMed, 
CINAHL Plus and Academic Search Premier included “sertraline” and “generalized anxiety.” 
All articles chosen for this systematic review include outcomes that are patient-oriented 
(POEMs) and are relevant to the author’s clinical question. Articles selected fit the inclusion 
criteria of randomized control trials published after 2008 with no other systematic review, meta-
analysis or articles published in the Cochrane database regarding the same clinical question. 
Studies were excluded if they were published before 2008 and not of a primary research design. 
Key statistics include p-values, confidence intervals, mean change from baseline and standard 
deviation. Additional relevant statistics reported included numbers needed to treat (NNT), 
experimental event rate (EER), control event rate (CER), absolute risk reduction (ARR), relative 
risk (RR) and relative benefit increased (RBI). 
Table 1: Demographics and Characteristics of Included Studies 













107 20-60 Any male or 
female 
patient aged 
20-60 with a 
diagnosis of 
GAD and an 
HAMA total 
score >20 




disorders or somatic 
dysfunction (DM, HTN, 
cardiomyopathy, thyroid 
dysfunction). 
0 Sertraline with 
a mean dose of 
150 mg/day x 4 
weeks 
vs. Pregabalan 
with a mean 
dose of  225 







46 >60 Any male or 
female with 
a DSM-IV 
Patients w/ severe 
depressive symptoms or 
grief reaction in the past 
0 Oral sertraline 
50-100 mg/day 
x 8 weeks 








 In this review, three RCTs were employed, two double blinded and one single blinded, 
with the measured outcomes being patient oriented evidence that matters (POEMs). The primary 
POEM measured in this review was reduction in symptoms of anxiety. This was ascertained 
using interviews with patients and several different scales. Cvjetkovic et al1 and Mokhber et al11 
used the Hamilton Rating Scale for Anxiety (HRSA). Walkup et al12 used four different scales, 
including the Clinical Global Impression-Improvement Scale, the Pediatric Anxiety Rating 








6 months; patients w/ 
any clinically important 
medical disease or 
abnormality on PE (e.g. 
head trauma, thyroid 
issues, acute heart 
disease); pts. w/ other 
Axis I psychiatric 
disorders or cognitive 
disturbances; pts. who 
used other drugs with 
psychotropic effects 
within 4 weeks prior to 
the study.  
increased 
gradually 












488 7-17 Children 
between the 
ages of 7 









Children w/ unstable 
medical conditions or 
who were refusing to 
attend school due to 
anxiety or were 
unresponsive to two 
trials of SSRIs; sexually 
active/ pregnant females 
not using birth control; 
children receiving 
psychoactive 
medications other than 
stable doses of 
stimulants w/ psychiatric 
diagnoses; children who 
were an acute risk to 







25 mg/day and 
adjusted up to 
200 mg/day by 
week 8 vs. 8 
weeks of CBT 








Scale. Data was statistically measured via the patient’s self-reported reduction in anxiety 
symptoms using the above scales and reported either in terms of whether or not patients 
responded positively to treatment or as a change in means over the course of the study, using p-
values and confidence intervals to determine the clinical significance of the data.  
RESULTS 
 
 To determine if the effect of sertraline on anxiety symptoms was advantageous the 
three articles being evaluated used p-values. Cvjetkovic1 claimed statistical significance if the p-
value was <0.05. Mokhber11 and Walkup12 claimed statistical significance with a p-value of 
<0.01. In Cvjetkovic-Bosnjak et al1 107 patients aged 20-60 at an outpatient psychiatric clinic 
were randomly assigned to 4 weeks of treatment with pregabalin or sertraline. A mean daily dose 
of 150 mg of sertraline and a mean daily dose of 225 mg of pregabalin was given.1 Patients 
attended weekly visits with two different psychiatrists to assess the severity of their anxiety 
symptoms, and at the end of the four week regimen, the final effectiveness and side effects 
assessments were made by the same psychiatrist that did the baseline evaluations.1 patients 
treated with sertraline had a 10.1-point reduction in their overall HRSA score after 4 weeks1 
(Table 2). Additionally, 96% of patients treated with sertraline showed ratings of very much 
improved.1 This study found that the most frequently reported adverse event amongst those 
treated with sertraline was nausea (13%), but that the adverse events were short-lasting and of 
mild intensity.1 
Table 2. Change in Hamilton Anxiety Scale scores in patients with generalized anxiety 
disorder treated 4 weeks with sertralineα 
 
HRSA Scores Baseline Week 1 Week 3 Week 4 
Sertraline 24.00 +1.2 23.50 + 0.9 14.70 + 1.0 13.90 + 0.2 
Pregabalan 23.60 +2.6 18.10 + 2.2 15.20 + 1.3 14.20 + 0.7 
                α Data derived directly from Cvjetkovic-Bosnjak et al1 




 Mokhber et al. studied 46 patients aged >60 with a clinical diagnosis of GAD. There 
were 21 patients receiving a daily dose of 50-100 mg of sertraline and 25 patients receiving a 
daily dose of 10-15 mg of buspirone, and the dosages were gradually increased according to a 
fixed incremental schedule.9 Efficacy of these two medications was assessed by a psychiatrist 
blind to the treatment after 2, 4, and 8 weeks.9 In this study, the mean score on the Hamilton 
Rating Scale for Anxiety after 8 weeks also significantly decreased in the sertraline group.11 For 
the purpose of this review, the focus will remain on week 4 as an endpoint. (Table 3). By week 4, 
there was a nearly 25% decrease in HRSA scores for patients treated with sertraline.11 No 
clinically significant serious adverse events were observed during the study period, and no one 
withdrew from the study.11 
Table 3: Mean HRSA scores for patients treated with sertraline and buspirone weeks 0-4α 
HRSA Scores Week 0 Week 2 Week 4  
Sertraline 28.63 +/- 5.19 28.48 +/- 4.90 21.48 +/- 4.64 
Buspirone 28.84 +/-5.15 18.96 +/- 5.81 15.60 +/- 5.45 
                     α Data derived directly from Mokhber et al11 
 Finally, Walkup et al. conducted a two-phase multicenter RCT for 488 children and 
adolescents between the ages of 7 and 17 years with a clinical diagnosis of GAD. Phase 1 was a 
12-week trial of short-term treatment comparing cognitive behavioral therapy, sertraline, and 
their combination with a placebo drug, and phase 2 was a 6 month open extension for patients 
who had a response in phase 1. In phase 1, which is the primary focus of this review, CBT 
involved fourteen 60 minute sessions, while pharmacotherapy involved 8 sessions of 30-60 
minutes each in which subjects rated the severity of their anxiety symptoms.12 Sertraline and a 
matching placebo were administered on a fixed-flexible schedule beginning with 25 mg/day and 
adjusted up to 200 mg/day by week 8.12 Patients were monitored for a total of 12 weeks via 
interviews administered by independent evaluators who were unaware of study group 
assignments.10 For the purpose of this review, week 4 will be the endpoint studied.  This study 




used several different scales to measure outcomes. The Clinical Global Impression Improvement 
Scale demonstrated whether or not patients had a positive response to therapy, with a score from 
1-7 in which 1 indicated very much improved and 2 indicated much improved.12 The study found 
that the percentages of children with a score < 3 at 4 weeks was 18.8% in the sertraline group, 
exceeding those with a response to CBT or placebo in the same time frame12 (Table 4). 
Table 4. Patients (%) with response to sertraline, placebo, CBT, and combination therapy 
on the Clinical Global Impression-Improvement Scale with score <3 through week 4 α 
Clinical Global Impression 
Improvement Scale  
Week 4 outcomes 
% with response to sertraline 18.8  
% with response to placebo 6.6 
% with response to CBT 9.3 
% with response to combination 
therapy 
21.4 
αData derived directly from Walkup et al12 
Scores on the Pediatric Anxiety Rating Scale range from 0-30, with scores higher than 13 
consistent with moderate levels of anxiety and a diagnosis of an anxiety disorder.12 By the end of 
4 weeks, there was nearly 25% rate of improvement in the sertraline group12 (Table 5). Scores on 
the Clinical Global Impressions Severity Scale and the Children’s Global Assessment Scale 
demonstrated similar levels of efficacy for sertraline by week 4.12 
Table 5: Change in Pediatric Anxiety Rating Scale in patients treated with 4 weeks of 
sertraline or placebo or CBT or combination therapyα 
Pediatric Anxiety 
Rating Scale 
Baseline Week 4 
Sertraline 18.8 +/- 3.9 14.2 +/- 4.0 
Placebo 19.6 +/- 3.9 16.0 +/- 4.1 
Cognitive 
behavioral therapy 
18.9 +/- 3.9 16.0 +/- 3.9 
Combination 
therapy 
19.4 +/- 3.9 14.6 +/- 3.9 
αData derived directly from Walkup et al12 






 While these studies demonstrate the efficacy of sertraline at reducing symptoms of 
anxiety in those with a diagnosis of GAD, they were not without limitations. Cvjetkovic-Bisnjak 
et al. was a small single center study with a limited age group and excluded patients with many 
comorbidities, limiting the generalizability of the study.1 Mokhber at al. primarily focused on 
GAD in the elderly population, and was again limited by its small sample size.9 Additionally, the 
association between medical illness, cognitive impairment, depression and GAD in the elderly 
excluded several subjects, thus limiting the generalizability of the study.11 Walkup et al. 
acknowledged that despite intense outreach, the sample did not include the most 
socioeconomically disadvantaged children.12 Additionally, exclusion of children and teens with 
major depression and pervasive developmental disorders may have limited the generalizability of 
the results to these populations.12  
 A final limitation of all three studies are the scales used to measure the outcomes. As 
noted, several different scales of measurement were used to assess the severity of anxiety 
symptoms. While the scales used are helpful in obtaining statistics about the specific populations 
studied, a more conclusive result may be obtained if a universal scale was utilized.  For example, 
the Clinical Useful Anxiety Outcome Scale is one example of a standardized scale that may be 
used. A standardized scale will strengthen the validity of future studies on this topic.  
 In terms of cost, sertraline appears to be an affordable option to treat GAD. In June, 2006, 
after the U.S patent for Zoloft expired, sertraline was introduced in generic form worldwide.14 
Panzarino and Nash found that among the established SSRIs, drug acquisition costs were lowest 
for sertraline and paroxetine, and both are available in extended dosage forms to reduce the need 
for multi-tablet therapy.14 Similarly, Ifigenia et al. found sertraline to be the most cost-effective 




drug for patients with GAD.15 While sertraline is often recommended in combination with CBT,  
Creswell et al. found that while cognitive behavioral therapy is effective, it is expensive and 
trained therapists are scarce.16 In light of this, sertraline may be  a more cost-effective method of 
solo therapy for GAD for those who do not have access to an affordable and qualified therapist.  
 More attention should be given to the negative side effects and drug interactions of 
sertraline. In October of 2004, the FDA issued a black box warning for sertraline indicating that 
the use of the drug in adolescents may increase the risk of suicidal ideations and behaviors.17 
Additionally, when compared to other SSRIs, sertraline tends to be associated with a higher rate 
of psychiatric side effects and diarrhea.18 If used during pregnancy, sertraline increases risk of 
preterm delivery, low birth weight and lower APGAR scores.19 While sertraline may be effective 
for treating GAD, the side effects cannot be ignored and should be further examined to determine 
if the risks outweigh the benefits of this drug.  
CONCLUSION 
 
 From these three studies, it can be concluded that sertraline is an effective therapy for 
reducing symptoms of anxiety in those diagnosed with GAD. In all three studies, a statistically 
significant decrease in symptom severity was achieved in patients who underwent a daily trial of 
sertraline. In order to further assess the efficacy of sertraline as solo therapy for GAD, it would 
be beneficial to complete further studies with larger and more diverse population. The long-term 
safety, tolerability, and efficacy of sertraline should  be further  investigated, but there is benefit 
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